This docum ent does not reflect the intent or official position of the bill sponsor or House of Representatives.
STORAGE NAME: h1135b.JUA
DATE: 3/18/2023
HOUSE OF REPRESENTATIVES STAFF ANALYSIS
BILL #: HB 1135 Nitazene Derivatives
SPONSOR(S): Overdorf
TIED BILLS: IDEN./SIM. BILLS: SB 736
REFERENCE ACTION ANALYST STAFF DIRECTOR or
BUDGET/POLICY CHIEF
1) Criminal Justice Subcommittee 17 Y, 0 N Leshko Hall
2) Justice Appropriations Subcommittee Saag Keith
3) Judiciary Committee
SUMMARY ANALYSIS
Federal and state law both classify controlled substances into five schedules. The scheduling determination for a
controlled substance is based on a substance’s potential for abuse and whether the substance has a currently
accepted medical use. The classifications range from a Schedule I substance, which has a high potential for
abuse and no accepted medical use; to a Schedule V substance, which has a low potential for abuse and an
accepted medical use. These schedules regulate the manufacture, distribution, preparation, and dispensing of
the substances listed therein.
The Legislature delegated to the Florida Attorney General the authority to adopt rules to schedule or reschedule
any substance which is not already controlled under s. 893.03, F.S., if the substance has the potential for abuse.
If the Attorney General finds that the scheduling of a substance in Schedule I of s. 893.03, F.S., on a temporary
basis is necessary to avoid an imminent hazard to the public safety, he or she may bypass certain requirements
and by rule schedule such substance in Schedule I.
Nitazene is a synthetic opioid, a subclass of benzimidazole-opioids, that can appear yellow, brown, or off-white
in color when in powder form, and is 10 to 20 times stronger than fentanyl, which itself is 50 to 100 times more
potent than morphine. Nitazene was created as potential pain reliever medication in the 1950s but has never
been approved for medical use in the United States based on early testing showing high rates of overdose and
potential for abuse. Drug Enforcement Administration laboratories have encountered this drug mixed into
heroin and fentanyl. Adding nitazene to another drug makes the drug more potent and addictive, and cheaper.
In other instances, it has been pressed into counterfeit pills and falsely marketed as pharmaceutical
medication.
On April 26, 2022, the Florida Attorney General filed Emergency Rule 2ER22-1 to add eight nitazene derivatives
to Schedule I of s. 893.03, F.S. The emergency rule became effective on the date of filing and will expire on
June 30, 2023. Ten nitazene derivatives have been added to the federal Controlled Substance Act as Schedule I
substances. These include the eight that the Florida Attorney General added through the emergency rule filed in
April 2022.
HB 1135 amends s. 893.03, F.S., to add nitazene derivatives to the list of Schedule I controlled substances
including, but not limited to: butonitazene, clonitazene, etodesnitazene, etonitazene, flunitazene,
isotodesnitazene, isotonitazene, metodesitazene, metonitazene, nitazene, N-desethyl etonitazene, N-desethyl
isotonitazene, N-piperidino etonitazene, N-pyrrolidino etonitazene, and protonitazene.
The bill may have a positive indeterminate impact on jail and prison beds by making the manufacture,
distribution, possession, or sale of more substances illegal which may result in more jail and prison
admissions.
The bill provides an effective date of October 1, 2023. STORAGE NAME: h1135b.JUA PAGE: 2
DATE: 3/18/2023
FULL ANALYSIS
I. SUBSTANTIVE ANALYSIS
A. EFFECT OF PROPOSED CHANGES:
Background
Florida Law
Controlled Substance Schedules
Chapter 893, F.S., the Florida Comprehensive Drug Abuse Prevention and Control Act, classifies
controlled substances
1
into five categories, called schedules. These schedules regulate the
manufacture, distribution, preparation, and dispensing of the substances listed therein. The
distinguishing factors between the different controlled substance schedules are the “potential for
abuse”
2
of the substance and whether there is a currently accepted medical use for the substance.
3
The controlled substance schedules are as follows:
Schedule I substances have a high potential for abuse and currently have no accepted medical
use in the United States and their use under medical supervision does not meet accepted safety
standards.
4
Schedule II substances have a high potential for abuse and have a currently accepted but
severely restricted medical use in the United States, and abuse of the substance may lead to
severe psychological or physical dependence.
5
Schedule III substances have a potential for abuse less than the substances contained in
Schedules I and II and have a currently accepted medical use in the United States, and the
abuse of the substance may lead to moderate or low physical dependence or high
psychological dependence, or in the case of anabolic steroids, may lead to physical damage.
6
Schedule IV substances have a low potential for abuse relative to substances in Schedule III
and have a currently accepted medical use in the United States, and abuse of the substance
may lead to limited physical or psychological dependence relative to the substances in
Schedule III.
7
Schedule V substances, compounds, mixtures, or preparation of substances have a low
potential for abuse relative to the substances in Schedule IV and have a currently accepted
medical use in the United States, and abuse of such compound, mixture, or preparation may
lead to limited physical or psychological dependence relative to the substances in Schedule IV.
8
Attorney General Emergency Scheduling Authority
The Legislature delegated to the Florida Attorney General the authority to adopt rules to schedule or
reschedule any substance which is not already controlled under s. 893.03, F.S., if the substance has
the potential for abuse.
9
Proof of potential for abuse can be based upon a showing that these activities
are already taking place, or upon a showing that the nature and properties of the substance make it
reasonable to assume that there is a substantial likelihood that such activities will take place, in other
than isolated or occasional instances.
10
Any findings and conclusions provided by the U.S. Attorney
1
“Controlled substance” means any substance named or described in Schedules I-V of s. 893.03, F.S. S. 893.02(4), F.S.
2
“Potential for abuse” means that a substance has properties as a central nervous system stimulant or depressant or a hallucinogen
that create a substantial likelihood of its being: 1) used in amounts that create a hazard to the user’s health or safety of the community;
2) diverted from legal channels and distributed through illegal channels; or 3) taken on the user’s own initiative rather than on the basis
of professional medical advice. S. 893.02(22), F.S.
3
See s. 893.03, F.S.
4
S. 893.03(1), F.S.
5
S. 893.03(2), F.S.
6
S. 893.03(3), F.S.
7
S. 893.03(4), F.S.
8
S. 893.03(5), F.S.
9
S. 893.035(2), F.S.; Potential for abuse has the same meaning as provided in s. 893.02(22), F.S.
10
S. 893.035(3)(a), F.S. STORAGE NAME: h1135b.JUA PAGE: 3
DATE: 3/18/2023
General with respect to any substance is admissible as evidence in any rulemaking proceeding,
including an emergency rulemaking proceeding.
11
If the Attorney General finds that the scheduling of a substance in Schedule I of s. 893.03, F.S., on a
temporary basis is necessary to avoid an imminent hazard to public safety, he or she may by rule
12
schedule such substance in Schedule I if the substance is not listed in any other schedule of s. 893.03,
F.S. The Attorney General shall be required to consider, with respect to his or her finding of imminent
hazard to public safety, only:
The substance’s potential for abuse;
13
The substance’s history and current pattern of abuse;
The scope, duration, and significance of abuse;
What, if any, risk there is to the public health;
14
Diversion from legitimate channels, if any; and
Clandestine importation, manufacture, or distribution.
15
The Attorney General must provide specific facts and reasons for finding an immediate danger to the
public health, safety, or welfare.
16
The Attorney General shall report to the Legislature by March 1 of
each year concerning any rules adopted to schedule or reschedule any substance during the previous
year. Each such rule expires on the following June 30 unless the Legislature adopts the provisions in
statute.
17
Department of Legal Affairs Emergency Rule 2ER22-1 (2022)
On April 26, 2022, the Attorney General filed Emergency Rule 2ER22-1 to add the following nitazene
derivatives to Schedule I of s. 893.03, F.S.:
Butonitazene;
Etodesnitazene/etazene;
Flunitazine;
Metodesnitazene;
Metonitazene;
N-pyrrolidino etonitazene/etonitazepyne;
Protonitazene; and
Isotonitazene.
18
The emergency rule became effective on the date of filing and will expire on June 30, 2023, if the
Legislature does not adopt the provisions through amendment to s. 893.03, F.S. The Attorney General
found:
That the chemical structures of the nitazene compounds are dissimilar to any currently
scheduled substance in Schedule I under s. 893.03, F.S.
That nitazenes have no currently accepted medical use.
The potential for abuse of nitazene compounds is significant given that many of them are
equivalent to or several times more potent than fentanyl and morphine.
That many nitazene derivatives have already been added to Schedule I of the federal Controlled
Substances Act.
11
Id.
12
In an emergency rulemaking proceeding, the Attorney General may proceed without regard to the requirements to request a medical
and scientific evaluation of the substance from and consider recommendations regarding scheduling from the Department of Health and
the Department of Law Enforcement. S. 893.035(5) and (7), F.S.
13
S. 893.035(3)(a), F.S.
14
S. 893.035(4)(d-f), F.S.
15
S. 893.035(7), F.S.
16
S. 120.54(4)(a)3., F.S.
17
These expiration provisions are notwithstanding the 90-day expiration described in s. 120.54(4)(c), F.S.
18
R. 2ER22-1, Vol. 48, No. 82, Fla. Admin. Reg. (April 27, 2022), https://www.flrules.org/gateway/ruleno.asp?id=2ER22-
1&PDate=4/27/2022&Section=4 (last visited Mar. 14, 2023). STORAGE NAME: h1135b.JUA PAGE: 4
DATE: 3/18/2023
That synthetic opioid overdose deaths are on the rise nationwide and, in Florida, at least fifteen
deaths since 2020 have been confirmed related to nitazene derivatives.
19
Federal Law
The federal Controlled Substances Act
20
(CSA) also classifies controlled substances into schedules
based on the potential for abuse and whether there is a currently accepted medical use for the
substance. The U.S. Attorney General is required to consider the following when determining where to
schedule a substance:
21
The substance’s actual or relative potential for abuse;
Scientific evidence of the substance’s pharmacological effect, if known;
The state of current scientific knowledge regarding the substance;
The substance’s history and current pattern of abuse;
The scope, duration, and significance of abuse;
What, if any, risk there is to public health;
The substance’s psychic or physiological dependence liability; and
Whether the substance is an immediate precursor of a substance already controlled.
Nitazene Derivatives
The following nitazene derivatives have been added to the CSA as Schedule I controlled substances:
Butonitazene;
Clonitazene;
Etodesnitazene/etazene;
Etonitazine;
Flunitazine;
Isotonitazene;
Metodesnitazene;
Metonitazene;
N-pyrrolindino etonitazene/etonitazepyne; and
Protonitazene.
The above nitazene derivates, except for isotonitazene, were scheduled effective April 12, 2022.
Isotonitazene was scheduled effective August 20, 2020.
22
Nitazene
Nitazene is a synthetic opioid, a subclass of benzimidazole-opioids, that can appear yellow, brown, or
off-white in color when in powder form, and is 10 to 20 times stronger than fentanyl, which itself is 50 to
100 times more potent than morphine.
23
Nitazene was created as potential pain reliever medication in
the 1950s but has never been approved for medical use in the United States based on early testing
showing high rates of overdose and potential for abuse.
24
19
Florida Attorney General, Findings of the Attorney General in Support of Emergency Rule 2ER22-1,
http://myfloridalegal.com/webfiles.nsf/WF/CPAL-CDUPT2/$file/Web+Link.pdf (last visited Mar. 14, 2023).
20
21 U.S.C. § 812.
21
21 U.S.C. § 811(c).
22
Drug Enforcement Administration (DEA), Controlled Substances,
https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf (last visited Mar. 14, 2023); DEA, Scheduling Actions,
https://www.deadiversion.usdoj.gov/schedules/orangebook/a_sched_alpha.pdf (last visited Mar. 14, 2023).
23
Opioid Treatment, Nitazenes: New Opioids 20 Times Stronger Than Fentanyl, https://www.opioidtreatment.net/blog/nitazenes/ (last
visited Mar. 14, 2023); DEA, New, Dangerous Synthetic Opioid in D.C., Emerging in Tri-State Area,
https://www.dea.gov/stories/2022/2022-06/2022-06-01/new-dangerous-synthetic-opioid-dc-emerging-tri-state-area (last visited Mar. 14,
2023); National Institute on Drug Abuse, Fentanyl, https://www.drugabuse.gov/publications/drugfacts/fentanyl (last visited Mar. 14,
2023).
24
DEA, Benzimidazole-Opiods: Other Name: Nitazenes, https://www.deadiversion.usdoj.gov/drug_chem_info/benzimidazole-
opioids.pdf#search=nitazenes (last visited Mar. 14, 2023); Centers for Disease Control and Prevention, Notes from the Field: Nitazene-
Related Deaths – Tennessee, 2019-2021, https://www.cdc.gov/mmwr/volumes/71/wr/mm7137a5.htm (last visited Mar. 14, 2023);
Addiction Center, Nitazene Addiction and Abuse, https://www.addictioncenter.com/opiates/nitazenes/ (last visited Mar. 14, 2023). STORAGE NAME: h1135b.JUA PAGE: 5
DATE: 3/18/2023
Drug Enforcement Administration laboratories have encountered this drug mixed into heroin and
fentanyl. Adding nitazene to another drug makes the drug more potent and addictive, and cheaper.
25
In
other instances, it has been pressed into counterfeit pills and falsely marketed as pharmaceutical
medication.
26
Many people who have died of a nitazene overdose were unaware they were ingesting
nitazene given the frequency with which it is mixed with other drugs and purposely mislabeled.
27
Isotonitazene was the most common cause of nitazene-related deaths nationwide in 2020. In 2021,
however, nitazene-related deaths were most frequently caused by metonitazene.
28
Effect of Proposed Changes
HB 1135 amends s. 893.03, F.S., to add nitazene derivatives to the list of Schedule I controlled
substances including, but not limited to:
Butonitazene;
Clonitazene;
Etodesnitazene;
Etonitazene;
Flunitazene;
Isotodesnitazene;
Isotonitazene;
Metodesitazene;
Metonitazene;
Nitazene;
N-desethyl etonitazene;
N-desethyl isotonitazene;
N-piperidino etonitazene;
N-pyrrolidino etonitazene; and
Protonitazene.
As such, under the bill, Florida law regulates the manufacture, distribution, preparation, and dispensing of
such nitazene derivatives.
The bill provides an effective date of October 1, 2023.
B. SECTION DIRECTORY:
Section 1: Amends s. 893.03, F.S., relating to standards and schedules.
Section 2: Provides an effective date of October 1, 2023.
25
GoodRx Health, Nitazenes: What to Know About the Illegal Opioids That Can Be More Potent Than Fentanyl,
https://www.goodrx.com/classes/opioids/nitazene-synthetic-opioid (last visited Mar. 14, 2023).
26
Supra note 23.
27
Supra note 23.
28
Supra note 26. STORAGE NAME: h1135b.JUA PAGE: 6
DATE: 3/18/2023
II. FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT
A. FISCAL IMPACT ON STATE GOVERNMENT:
1. Revenues:
None.
2. Expenditures:
See Fiscal Comments.
B. FISCAL IMPACT ON LOCAL GOVERNMENTS:
1. Revenues:
None.
2. Expenditures:
See Fiscal Comments.
C. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR:
None.
D. FISCAL COMMENTS:
The bill may have a positive indeterminate impact on jail and prison beds by making the manufacture,
distribution, possession, or sale of more substances illegal which may result in more jail and prison
admissions.
III. COMMENTS
A. CONSTITUTIONAL ISSUES:
1. Applicability of Municipality/County Mandates Provision:
Not Applicable. This bill does not appear to require counties or municipalities to spend funds or take
action requiring the expenditures of funds; reduce the authority that counties or municipalities have
to raise revenues in the aggregate; or reduce the percentage of state tax shared with counties or
municipalities.
2. Other:
None.
B. RULE-MAKING AUTHORITY:
None.
C. DRAFTING ISSUES OR OTHER COMMENTS:
None.
IV. AMENDMENTS/COMMITTEE SUBST ITUTE CHANGES